Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Sep 15;214(6):832-5.
doi: 10.1093/infdis/jiw067. Epub 2016 Feb 16.

A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response

Anna P Durbin  1 , Beth D Kirkpatrick  2 , Kristen K Pierce  2 , Marya P Carmolli  2 , Cecilia M Tibery  1 , Palmtama L Grier  1 , Noreen Hynes  1 , Kari Opert  1 , Adrienne P Jarvis  2 , Beulah P Sabundayo  1 , Benjamin D McElvany  2 , Eli A Sendra  2 , Catherine J Larsson  2 , Matthew Jo  1 , Janece M Lovchik  1 , Catherine J Luke  3 , Mary C Walsh  2 , Ellen A Fraser  2 , Kanta Subbarao  3 , Stephen S Whitehead  3
Affiliations
Clinical Trial

A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response

Anna P Durbin et al. J Infect Dis. .

Abstract

The ideal dengue vaccine will provide protection against all serotypes of dengue virus and will be economical and uncomplicated in its administration. To determine the ability of a single dose of the live attenuated tetravalent dengue vaccine TV003 to induce a suitable neutralizing antibody response, a placebo-controlled clinical trial was performed in 48 healthy adults who received 2 doses of vaccine or placebo administered 12 months apart. Evaluation of safety, vaccine viremia, and neutralizing antibody response after each dose indicated that the first dose of vaccine was capable of preventing infection with the second dose, thus indicating that multiple doses are unnecessary.

Clinical trials registration: NCT01782300.

Keywords: clinical trial; dengue vaccine; live attenuated tetravalent.

PubMed Disclaimer

Comment in

References

    1. Bhatt S, Gething PW, Brady OJ et al. . The global distribution and burden of dengue. Nature 2013; 496:504–7. - PMC - PubMed
    1. Barniol J, Gaczkowski R, Barbato EV et al. . Usefulness and applicability of the revised dengue case classification by disease: multi-centre study in 18 countries. BMC Infect Dis 2011; 11:106. - PMC - PubMed
    1. Innis BL. Antibody responses to dengue virus infection. In: Gubler DJ, Kuno G, eds. Dengue and dengue hemorrhagic fever. Cambridge: CAB International, 1997:221–43.
    1. Halstead SB. Antibodies determine virulence in dengue. Ann N Y Acad Sci 2009; 1171(suppl 1):E48–56. - PubMed
    1. Guzman MG, Kouri GP, Bravo J, Soler M, Vazquez S, Morier L. Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg 1990; 42:179–84. - PubMed

Publication types

MeSH terms

Associated data